FY2025 · ended Dec 31, 2025 · Revenue $40.52M, +7.4% YoY · Filed Mar 2, 2026
Alpha Teknova, Inc. (TKNO) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $40.5 million and a net loss of $17.3 million. Free cash flow was -$9.8 million. As of Jun 30, 2026 it held $17.4 million in cash and investments and $27.4 million in total debt.
Revenue (TTM)
$43.70M
+12.3% vs year-ago TTM
Net income (TTM)
$-16.77M
+22.0% vs year-ago TTM
Operating cash flow (TTM)
$-6.27M
+31.8% vs year-ago TTM
Free cash flow (TTM)
$-7.35M
+30.0% vs year-ago TTM
EPS (TTM)
$-0.31
+22.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
53.59M
+0.3% vs prior year
Net cash
$-9.97M
as of Jun 30, 2026
Operating margin
-36.2%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- TKNO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hollister, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1850902
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $40.5M | $37.7M | $36.7M | $41.4M | $36.9M |
| Operating income | -$17.0M | -$26.1M | -$35.6M | -$49.7M | -$12.0M |
| Net income | -$17.3M | -$26.7M | -$36.8M | -$47.5M | -$9.8M |
| Diluted EPS | -$0.32 | -$0.57 | -$1.16 | -$1.69 | -$0.61 |
| Operating cash flow | -$8.6M | -$12.4M | -$18.8M | -$27.4M | -$9.1M |
| Free cash flow | -$9.8M | -$13.5M | -$26.7M | -$55.5M | -$28.9M |
| Total assets | $103.6M | $118.8M | $128.6M | $152.3M | $166.5M |
| Total liabilities | $34.8M | $36.4M | $38.6M | $52.4M | $23.3M |
| Stockholders' equity | $68.8M | $82.4M | $90.0M | $99.9M | $143.2M |
| Cash and investments | $21.3M | $30.4M | $28.5M | — | $87.5M |
| Total debt | $28.3M | $26.1M | $30.5M | $42.3M | $11.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
Oct 21, 2026 | Oct 20, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 1, 2026 | May 27, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 221 Alpha Teknova, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.